表紙
市場調查報告書
商品編碼
1027977

癌症治療用查核點抑制劑的全球市場分析 (2021年∼2031年):各類別 (PD1/PD-L1/CTLA-4抑制劑,免疫佐劑,免疫調節藥物,細胞激素目標)、各用途的預測,主要國家分析,主要企業,新型冠狀病毒感染疾病 (COVID-19)

Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031: Forecasts by Category, PD1/PD-L1/CTLA-4 Inhibitors, Immuno Adjuvants, Immunomodulators, Cytokines Targets, Application, Leading National Market Analysis/Companies, COVID-19

出版日期: | 出版商: Visiongain Ltd | 英文 612 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球癌症治療用查核點抑制劑的市場相關分析,產品概要和市場基本結構、最新形勢,主要的促進、阻礙因素,市場規模的估計值、預測值 (2021年∼2031年),各類別 (PD1/PD-L1/CTLA-4抑制劑,免疫佐劑,免疫調節藥物,細胞激素目標)、各用途及各地區、主要國家詳細趨勢,主要企業的簡介,COVID-19影響與復甦情境等彙整資訊,為您概述為以下內容。

本文中的圖表

目錄

第1章 分析概要

第2章 摘要整理

第3章 查核點抑制劑產業結構

  • 概要
    • 抑制性免疫查核點標的
    • 免疫代謝調節標的
    • CAR-T細胞

第4章 全球市場動態

  • 全球市場的目前趨勢
  • 推動市場要素
  • 阻礙市場要素
  • 全球市場的機會
  • 全球市場的課題

第5章 全球查核點抑制劑市場分析

  • 全球市場預測
  • 全球市場規模:估計值、預測值
    • COVID-19前的市場情境
    • COVID-19後的市場情境 (V字型/U字型/W字型/L字型的復甦分析)

第6章 全球市場的明細:各類別

  • 市場區隔概要
    • PD-1抑制劑
    • PD-L1抑制劑
    • CTLA-4抑制劑
    • 細胞激素目標
    • 免疫佐劑
    • 免疫調節劑
    • COVID-19前的市場情境
    • COVID-19後的市場情境 (V字型/U字型/W字型/L字型的復甦分析)

第7章 全球市場的明細:PD1抑制劑

  • 市場區隔概要
    • PD-1/PD-L1代理商:概要
    • PEMBROLIZUMAB (Keytruda),Merck & Co.
    • Nivolumab (Opdivo),BMS
    • Atezolizumab (Tecentriq),Genentech
    • Cemiplimab (Libtayo),Regeneron/Sanofi
    • COVID-19前的市場情境
    • COVID-19後的市場情境 (V字型/U字型/W字型/L字型的復甦分析)
  • PD-L1抑制劑:全球市場的明細
    • Avelumab (Bavencio),Merck KGaA/Pfizer
    • Durvalumab (Imfinzi),AstraZeneca
    • COVID-19前的市場情境
    • COVID-19後的市場情境 (V字型/U字型/W字型/L字型的復甦分析)

第8章 全球市場的明細:CTLA-4抑制劑

  • 市場區隔概要
    • COVID-19前的市場情境
    • COVID-19後的市場情境(V,W,U,L字型的復甦分析)

第9章 全球市場的明細:細胞激素目標

第10章 全球市場的明細:免疫佐劑

第11章 全球市場的明細:免疫調節劑

第12章 全球市場的明細:各用途

  • 市場區隔概要
    • 肺癌症的治療
    • 腎癌症的治療
    • 血液癌症的治療
    • 膀胱癌的治療
  • COVID-19前的市場情境
  • COVID-19後的市場情境 (V字型/U字型/W字型/L字型的復甦分析)

第13章 全球查核點抑制劑市場:各地區

第14章 北美的查核點抑制劑市場分析

  • 北美市場預測
  • 北美的市場規模:估計值、預測值
    • COVID-19前的市場情境
    • COVID-19後的市場情境 (V字型/U字型/W字型/L字型的復甦分析)
  • 各國市場規模
  • 各類別的市場規模
  • PD-1抑制劑的市場規模
  • PD-L1抑制劑的市場規模
  • CTLA-4抑制劑的市場規模
  • 細胞激素目標的市場規模
  • 各用途的市場規模
  • 免疫佐劑的市場規模
  • 免疫調節劑的市場規模
  • 美國市場
    • COVID-19前的市場情境
    • COVID-19後的市場情境 (V字型/U字型/W字型/L字型的復甦分析)
  • 加拿大市場
  • 墨西哥市場

第15章 歐洲的查核點抑制劑市場分析

  • 歐洲市場預測
  • 歐洲的市場規模:估計值、預測值
  • 各國市場規模
  • 各類別的市場規模
  • PD-1抑制劑的市場規模
  • PD-L1抑制劑的市場規模
  • CTLA-4抑制劑的市場規模
  • 細胞激素目標的市場規模
  • 各用途的市場規模
  • 免疫佐劑的市場規模
  • 免疫調節劑的市場規模
  • 德國市場
  • 英國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 其他的歐洲各國的市場

第16章 亞太地區的查核點抑制劑市場分析

  • 亞太地區市場預測
  • 亞太地區的市場規模:估計值、預測值
  • 各國市場規模
  • 各類別的市場規模
  • PD-1抑制劑的市場規模
  • PD-L1抑制劑的市場規模
  • CTLA-4抑制劑的市場規模
  • 細胞激素目標的市場規模
  • 各用途的市場規模
  • 免疫佐劑的市場規模
  • 免疫調節劑的市場規模
  • 中國市場
  • 印度市場
  • 日本市場
  • 韓國市場
  • 澳洲市場
  • 其他的亞太地區各國的市場

第17章 南美、中東、非洲 (LAMEA)的查核點抑制劑市場分析

  • LAMEA市場預測
  • LAMEA的市場規模:估計值、預測值
  • 各國市場規模
  • 各類別的市場規模
  • PD-1抑制劑的市場規模
  • 各PD-L1抑制劑的市場規模
  • 各CTLA-4抑制劑的市場規模
  • 細胞激素各目標的市場規模
  • 各用途的市場規模
  • 各免疫佐劑的市場規模
  • 免疫調節劑各的市場規模
  • 巴西市場
  • 南非市場
  • 沙烏地阿拉伯市場
  • 土耳其市場
  • 阿拉伯聯合大公國 (UAE) 市場
  • 其他的LAMEA各國的市場

第18章 主要企業簡介

  • 競爭情形
    • 全球市場的事業合作、聯盟
  • AGENUS INC.
  • Agilent Technologies
  • AbbVie Inc.
  • xencor
  • Ono pharmaceutical
  • Sanofi SA
  • Eli Lilly and Co
  • Kyowa Hakko Kirin
  • Novartis
  • Pfizer Inc.
  • Roche
  • Merck & Co.
  • Incyte
  • Regeneron pharmaceuticals Inc.
  • Amgen Inc
  • Bristol Myers Squibb
  • Heptares Therapeutics Ltd.

第19章 結論與建議

第20章 詞彙表

目錄
Product Code: PHA1142

Title:
Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
Forecasts by Category (PD1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, Cytokines Targets, Immuno Adjuvants, Immunomodulators), by PD1 Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo)), by PD-L1 Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), by CTLA-4 Inhibitors (Ipilimumab (Yervoy)), by Immuno Adjuvants (Imiquimod, Poly ICLC (Hiltonol)), by Immunomodulators (Pexidartinib (Turalio)), by Cytokines Targets (Aldesleukin, GM-CSF, Interferon Alfa-2a, Interferon Alfa-2b (Intron A®), Peginterferon alfa-2b (Sylatron®/PEGIntron®)), by Application (Lung Cancer Treatment, Renal Cancer Treatment, Blood Cancer Treatment, Bladder Cancer Treatment, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.

The Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

New Products/Therapy Launch Are Gaining Tractions in the Global Market

To distinguish their product offerings, new entrants into the oncology industry may use a variety of strategies. One strategy is to be first-in-class with a novel mechanism of action (MOA); another is to focus on an indication with a strong unmet need, thus providing a valuable new therapeutic choice for patients with few choices.

Increasing Support from FDA in the Approval Procedures

Currently, the FDA has licenced two anti-PD-1 antibodies: pembrolizumab and nivolumab. These medications, such as ipilimumab, were initially approved to treat advanced-stage melanomas but have since been approved to treat a variety of cancers. <>The third group of FDA-approved ICIs is antibodies against PD-L1. Urothelial carcinoma, non-small cell lung cancer (NSCLC), and Merkel cell carcinoma are treated with three anti-PD-L1 antibodies: atezolizumab, durvalumab, and avelumab. Anti-PD-1 and anti-PD-L1 antibodies have outperformed anti-CTLA-4 antibodies in clinical trials due to a combination of superior clinical efficacy and tolerability

What Are These Questions You Should Ask Before Buying A Market Research Report?

  • How is the checkpoint inhibitors for treating cancer market evolving?
  • What is driving and restraining the checkpoint inhibitors for treating cancer market?
  • How will each checkpoint inhibitors for treating cancer submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2031?
  • How will the market shares for each checkpoint inhibitors for treating cancer submarket develop from 2021 to 2031?
  • What will be the main driver for the overall market from 2021 to 2031?
  • Will leading checkpoint inhibitors for treating cancer markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2031 and which geographical region will lead the market in 2031?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the checkpoint inhibitors for treating cancer projects for these leading companies?
  • How will the industry evolve during the period between 2020 and 2031?
  • What are the implication of checkpoint inhibitors for treating cancer projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the checkpoint inhibitors for treating cancer market?
  • Where is the checkpoint inhibitors for treating cancer market heading? And how can you ensure you are at the forefront of the market?
  • What can be the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path? C-suite?

You need to discover how this will impact the checkpoint inhibitors for treating cancer market today, and over the next 10 years:

  • Our 612-page report provides 447 tables and 448 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • Contains in-depth analyse of global, regional and national sales and growth
  • Highlights for you the key successful trends, changes and revenue projections made by your competitors

This report tells you TODAY how the checkpoint inhibitors for treating cancer market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2031 and other analyses reveal the commercial prospects:

  • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising checkpoint inhibitors for treating cancer prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, V, L, W and U are discussed in this report.

Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Category

  • PD1 Inhibitors
  • PD-L1 Inhibitors
  • CTLA-4 Inhibitors
  • Cytokines Targets
  • Immuno Adjuvants
  • Immunomodulators

Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by PD1 Inhibitors

  • Pembrolizumab (Keytruda)
  • Nivolumab (Opdivo)
  • Cemiplimab (Libtayo)

Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by PD-L1 Inhibitors

  • Atezolizumab (Tecentriq)
  • Avelumab (Bavencio)
  • Durvalumab (Imfinzi)

Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by CTLA-4 Inhibitors

  • Ipilimumab (Yervoy)

Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Immuno Adjuvants

  • Imiquimod
  • Poly ICLC (Hiltonol)

Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Immunomodulators

  • Pexidartinib (Turalio)

Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Cytokines Targets

  • Aldesleukin
  • GM-CSF
  • Interferon Alfa-2a
  • Interferon alfa-2b (Intron A)
  • Peginterferon alfa-2b (Sylatron/PEG-Intron)

Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Application

  • Lung Cancer Treatment
  • Renal Cancer Treatment
  • Blood Cancer Treatment
  • Bladder Cancer Treatment
  • Other Application

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 20 leading national markets:

  • North America Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
  • U.S. Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Canada Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Mexico Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Europe Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
  • Germany Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Spain Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • United Kingdom Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • France Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Italy Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Rest of Europe Market Forecast & COVID Impact Analysis
  • Asia Pacific Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
  • China Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Japan Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • India Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Australia Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • South Korea Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Rest of Asia Pacific Market Forecast & COVID Impact Analysis
  • LAMEA Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
  • Brazil Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Turkey Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • South Africa Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • UAE Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
  • Rest of Latin America, Middle East and Africa

SAMPLE VIEW

The report also includes profiles and for some of the leading companies in the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • A Seagen Inc.,
  • Agenus Inc. (Agenus)
  • Agilent Technologies, Inc.
  • AbbVie Inc. (AbbVie)
  • Xencor, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Sanofi SA
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc. (Pfizer)
  • Roche Holding AG (Roche)
  • Merck & Co., Inc.
  • Incyte Corporation
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Clovis Oncology, Inc.
  • Heptares Therapeutics Ltd.

Overall world revenue for Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 in terms of value the market will surpass US$xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market report helps you?

In summary, our 610+ page report provides you with the following knowledge:

  • Revenue forecasts to 2031 for 4 regional and 20 key national markets - See forecasts for the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market- including company profiles for 20 of the major companies involved in the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market and leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Introduction to Checkpoint Inhibitors Market
  • 1.2 Global Checkpoint Inhibitors Market Overview
  • 1.3 What are the Objectives of this Report?
  • 1.4 What is the Scope of the Report?
  • 1.5 Checkpoint Inhibitors Market Definition
  • 1.6 Why You Should Read This Report
  • 1.7 What This Report Delivers
  • 1.8 Key Questions Answered by This Analytical Report Include:
  • 1.9 Who is This Report for?
  • 1.10 Research Methodology
    • 1.10.1 Primary Research
    • 1.10.2 Secondary Research
    • 1.10.3 Market Evaluation & Forecasting Methodology
  • 1.11 Frequently Asked Questions (FAQs)
  • 1.12 Associated Visiongain Reports
  • 1.13 About Visiongain

2 Executive Summary

3 Checkpoint Inhibitors Industry Structure

  • 3.1 Overview
    • 3.1.1 Inhibitory Immune Checkpoint Targets
    • 3.1.2 Immunometabolic Modulatory Targets
    • 3.1.3 CAR-T Cells

4 Global Market Dynamics

  • 4.1 Current Trends in the Global Market
  • 4.2 Market Driving Factors
    • 4.2.1 Peripheral Immune Responses Are Critical in Achieving Favourable Clinical Outcomes
    • 4.2.2 New Products/Therapy Launch Are Gaining Tractions in the Global Market
    • 4.2.3 Increasing Support from FDA in the Approval Procedures
  • 4.3 Market Restraining Factors
    • 4.3.1 Most Patients and Cancers Do Not Respond to Checkpoint Inhibitor Therapies
    • 4.3.2 Immune-Related Adverse Events Occurred, Restraining Further Research
    • 4.3.3 An Increased Risk of Thromboembolism
  • 4.4 Opportunities in the Global Market
    • 4.4.1 Unprecedented Advances in Cancer Immunotherapy
    • 4.4.2 Unmet Medical Needs
    • 4.4.3 New Combinations Therapies Creating New Opportunities
  • 4.5 Challenges in the Global Market
    • 4.5.1 Lack of Understanding in Regards to Checkpoint Inhibitors Mechanisms
    • 4.5.2 Resistance to Immune Checkpoint Inhibitors
    • 4.5.3 Whether irAE Presentation Correlates with ICI efficacy is a Challenge

5 Global Checkpoint Inhibitors Market Analysis

  • 5.1 Global Market Outlook
  • 5.2 Global Market Size Estimation and Forecast
    • 5.2.1 Pre-COVID-19 Market Scenario
    • 5.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

6 Global Market Breakdown by Category

  • 6.1 Segment Overview
    • 6.1.1 PD-1 inhibitor:
    • 6.1.2 PD-L1 Inhibitors:
    • 6.1.3 CTLA-4 Inhibitors:
    • 6.1.4 Cytokines Targets:
    • 6.1.5 Immuno Adjuvants
    • 6.1.6 Immunomodulators
    • 6.1.7 Pre-COVID-19 Market Scenario
    • 6.1.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

7 Global Market Breakdown by PD1 Inhibitors

  • 7.1 Segment Overview
    • 7.1.1 Introduction to PD-1/PD-L1 Agents
    • 7.1.2 Pembrolizumab (Keytruda), Merck & Co.
    • 7.1.3 Nivolumab (Opdivo), BMS
    • 7.1.4 Atezolizumab (Tecentriq), Genentech
    • 7.1.5 Cemiplimab (Libtayo), Regeneron/Sanofi
    • 7.1.6 Pre-COVID-19 Market Scenario
    • 7.1.7 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 7.2 Global Market Breakdown by PD-L1 Inhibitors
    • 7.2.1 Avelumab (Bavencio), Merck KGaA/Pfizer
    • 7.2.2 Durvalumab (Imfinzi), AstraZeneca
    • 7.2.3 Pre-COVID-19 Market Scenario
    • 7.2.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

8 Global Market Breakdown by CTLA-4 Inhibitors

  • 8.1 Segment Overview
    • 8.1.1 Pre-COVID-19 Market Scenario
    • 8.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

9 Global Market Breakdown by Cytokines Target

  • 9.1 Segment Overview
    • 9.1.1 Pre-COVID-19 Market Scenario
    • 9.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

10 Global Market Breakdown by Immuno Adjuvants

  • 10.1 Segment Overview
    • 10.1.1 Pre-COVID-19 Market Scenario
    • 10.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

11 Global Market Breakdown by Immuno Modulators

  • 11.1 Segment Overview
  • 11.2 Pre-COVID-19 Market Scenario
  • 11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

12 Global Market Breakdown by Application

  • 12.1 Segment Overview
    • 12.1.1 Lung Cancer Treatment
    • 12.1.2 Renal Cancer Treatment
    • 12.1.3 Blood Cancer Treatment
    • 12.1.4 Bladder Cancer Treatment
  • 12.2 Pre-COVID-19 Market Scenario
  • 12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

13 Global Checkpoint Inhibitors Market by Region

  • 13.1 Regional Market Size Estimation and Forecast
    • 13.1.1 Pre-COVID-19 Market Scenario
    • 13.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

14 North America Checkpoint Inhibitors Market Analysis

  • 14.1 North America Market Outlook
  • 14.2 North America Market Size Estimation and Forecast
    • 14.2.1 Pre-COVID-19 Market Scenario
    • 14.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.3 Country Market Size Estimation and Forecast
    • 14.3.1 Pre-COVID-19 Market Scenario
    • 14.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.4 North America Market Breakdown by Category
    • 14.4.1 Pre-COVID-19 Market Scenario
    • 14.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.5 North America Market Breakdown by PD-1 Inhibitors
    • 14.5.1 Pre-COVID-19 Market Scenario
    • 14.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.6 North America Market Breakdown by PD-L1 Inhibitors
    • 14.6.1 Pre-COVID-19 Market Scenario
    • 14.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.7 North America Market Breakdown by CTLA-4 Inhibitors
    • 14.7.1 Pre-COVID-19 Market Scenario
    • 14.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.8 North America Market Breakdown by Cytokines Target
    • 14.8.1 Pre-COVID-19 Market Scenario
    • 14.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.9 North America Market Breakdown by Application
    • 14.9.1 Pre-COVID-19 Market Scenario
    • 14.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.10 North America Market Breakdown by Immuno Adjuvants
    • 14.10.1 Pre-COVID-19 Market Scenario
    • 14.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.11 North America Market Breakdown by Immunomodulators
    • 14.11.1 Pre-COVID-19 Market Scenario
    • 14.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.12 US Checkpoint Inhibitors Market Analysis
    • 14.12.1 Clinical Use of Checkpoint Inhibitors is Growing Rapidly in the US
    • 14.12.2 Acceptance of Checkpoint Inhibitors for Treating Cancer
    • 14.12.3 Pre-COVID-19 Market Scenario
    • 14.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.13 Canada Checkpoint Inhibitors Market Analysis
    • 14.13.1 Patients Response to Checkpoint Inhibitor Therapies is Low in the Country
    • 14.13.2 Canada Market Is Expected to Grow at a Steady Pase
    • 14.13.3 Pre-COVID-19 Market Scenario
    • 14.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 14.14 Mexico Checkpoint Inhibitors Market Analysis
    • 14.14.1 Mexico Is One of the Research Centres for Checkpoint Inhibitors.
    • 14.14.2 PD-1/PD-L1 Inhibitors Continue to Change the Cancer Treatment Landscape in the Country
    • 14.14.3 Pre-COVID-19 Market Scenario
    • 14.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

15 Europe Checkpoint Inhibitors Market Analysis

  • 15.1 Europe Market Outlook
  • 15.2 Europe Market Size Estimation and Forecast
    • 15.2.1 Pre-COVID-19 Market Scenario
    • 15.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.3 Europe Market Size Estimation and Forecast by Region
    • 15.3.1 Pre-COVID-19 Market Scenario
    • 15.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.4 Europe Market Size Estimation and Forecast by Category
    • 15.4.1 Pre-COVID-19 Market Scenario
    • 15.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.5 Europe Market Size Estimation and Forecast by PD1 Inhibitors
    • 15.5.1 Pre-COVID-19 Market Scenario
    • 15.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.6 Europe Market Size Estimation and Forecast by PD-L1 Inhibitors
    • 15.6.1 Pre-COVID-19 Market Scenario
    • 15.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.7 Europe Market Size Estimation and Forecast by CTLA-4 Inhibitors:
    • 15.7.1 Pre-COVID-19 Market Scenario
    • 15.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.8 Europe Market Size Estimation and Forecast by Cytokines Targets:
    • 15.8.1 Pre-COVID-19 Market Scenario
    • 15.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.9 Europe Market Size Estimation and Forecast by Application
    • 15.9.1 Pre-COVID-19 Market Scenario
    • 15.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.10 Europe Market Size Estimation and Forecast by Immuno Adjuvants:
    • 15.10.1 Pre-COVID-19 Market Scenario
    • 15.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.11 Europe Market Size Estimation and Forecast by Immonumodulators
    • 15.11.1 Pre-COVID-19 Market Scenario
    • 15.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.12 Germany Checkpoint Inhibitors Market Analysis
    • 15.12.1 German Companies Pursuing Bispecific for The Next Generation of Checkpoint Inhibitors
    • 15.12.2 Companies Are Trying All Kinds of Combinations to Make Checkpoint Inhibitors Work for More People
    • 15.12.3 Pre-COVID-19 Market Scenario
    • 15.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.13 UK Checkpoint Inhibitors Market Analysis
    • 15.13.1 High Tumour Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer Types
    • 15.13.2 UK Checkpoint Inhibitors Market to Grow at a Decent Rate
    • 15.13.3 Pre-COVID-19 Market Scenario
    • 15.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.14 France Checkpoint Inhibitors Market Analysis
    • 15.14.1 Checkpoint Inhibitors Have Proven to Be Powerful Anti-Tumour Drugs
    • 15.14.2 French Companies Facing Failures in Checkpoint Inhibitors Research
    • 15.14.3 Pre-COVID-19 Market Scenario
    • 15.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.15 Italy Checkpoint Inhibitors Market Analysis
    • 15.15.1 Immunotherapy, And More Recently as Immuno-Oncology Therapies Are in Demand in The Country
    • 15.15.2 Strong Pharmacovigilance Infrastructure in The Country.
    • 15.15.3 Pre-COVID-19 Market Scenario
    • 15.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.16 Spain Checkpoint Inhibitors Market Analysis
    • 15.16.1 Prostate Cancer Is the Third Most Frequent Neoplasms in Spain
    • 15.16.2 Therapeutic Strategies to Enhance Immune-Responsiveness in Prostate Cancer
    • 15.16.3 Pre-COVID-19 Market Scenario
    • 15.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 15.17 Rest of Europe Checkpoint Inhibitors Market Analysis
    • 15.17.1 Pre-COVID-19 Market Scenario
    • 15.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

16 Asia-Pacific Checkpoint Inhibitors Market Analysis

  • 16.1 Asia-Pacific Market Outlook
    • 16.1.1 Chinese Checkpoint Inhibitors Are Poised to Change Global Market Dynamics
  • 16.2 Asia-Pacific Market Size Estimation and Forecast
    • 16.2.1 Pre-COVID-19 Market Scenario
    • 16.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.3 Country Market Size Estimation and Forecast
    • 16.3.1 Pre-COVID-19 Market Scenario
    • 16.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.4 Asia-Pacific Market Breakdown by Category
    • 16.4.1 Pre-COVID-19 Market Scenario
    • 16.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.5 Asia-Pacific Market Breakdown by PD-1 Inhibitors
    • 16.5.1 Pre-COVID-19 Market Scenario
    • 16.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.6 Asia-Pacific Market Breakdown by PD-L1 Inhibitors
    • 16.6.1 Pre-COVID-19 Market Scenario
    • 16.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.7 Asia-Pacific Market Breakdown by CTLA-4 Inhibitors
    • 16.7.1 Pre-COVID-19 Market Scenario
    • 16.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.8 Asia-Pacific Market Breakdown by Cytokines Targets
    • 16.8.1 Pre-COVID-19 Market Scenario
    • 16.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.9 Asia-Pacific Market Breakdown by Application
    • 16.9.1 Pre-COVID-19 Market Scenario
    • 16.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.10 Asia-Pacific Market Breakdown by Immuno Adjuvants
    • 16.10.1 Pre-COVID-19 Market Scenario
    • 16.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.11 Asia-Pacific Market Breakdown by Immonumodulators
    • 16.11.1 Pre-COVID-19 Market Scenario
    • 16.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.12 China Checkpoint Inhibitors Market Analysis
    • 16.12.1 China Supporting Local ICI Companies
    • 16.12.2 International ICI Brands Seeking Market Access in China
    • 16.12.3 Pre-COVID-19 Market Scenario
    • 16.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.13 India Checkpoint Inhibitors Market Analysis
    • 16.13.1 Increasing Breast Cancer Patients in India
    • 16.13.2 Surgery Is the Mainstay of Treatment of the Early Stages of Breast Cancer in The Country
    • 16.13.3 Upcoming Other Efficient Treatments such as Checkpoint Inhibitors in the Country
    • 16.13.4 Pre-COVID-19 Market Scenario
    • 16.13.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.14 Japan Checkpoint Inhibitors Market Analysis
    • 16.14.1 Use of Neoadjuvant Trials to Drive Progress in Head and Neck Cancer Immunotherapy
    • 16.14.2 Country is Focusing on Various Application Areas of Checkpoint Inhibitors
    • 16.14.3 Pre-COVID-19 Market Scenario
    • 16.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.15 South Korea Checkpoint Inhibitors Market Analysis
    • 16.15.1 More Emphasis Given On Radiation & Immunotherapy as Compared to CHI
    • 16.15.2 The Role of ICIs in Earlier Stages of Disease Is Unclear
    • 16.15.3 Pre-COVID-19 Market Scenario
    • 16.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.16 Australia Checkpoint Inhibitors Market Analysis
    • 16.16.1 Australia Heading the Research on Checkpoint Inhibitors
    • 16.16.2 Triebel spun out the Australian-European immunotherapy company
    • 16.16.3 Pre-COVID-19 Market Scenario
    • 16.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 16.17 Rest of Asia-Pacific Checkpoint Inhibitors Market Analysis
    • 16.17.1 Pre-COVID-19 Market Scenario
    • 16.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

17 LAMEA Checkpoint Inhibitors Market Analysis

  • 17.1 LAMEA Market Outlook
  • 17.2 LAMEA Market Size Estimation and Forecast
    • 17.2.1 Pre-COVID-19 Market Scenario
    • 17.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.3 Country Market Size Estimation and Forecast
    • 17.3.1 Pre-COVID-19 Market Scenario
    • 17.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.4 LAMEA Market Breakdown by Category
    • 17.4.1 Pre-COVID-19 Market Scenario
    • 17.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.5 LAMEA Market Breakdown by PD-1 Inhibitors:
    • 17.5.1 Pre-COVID-19 Market Scenario
    • 17.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.6 LAMEA Market Breakdown by PD-L1 Inhibitors:
    • 17.6.1 Pre-COVID-19 Market Scenario
    • 17.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.7 LAMEA Market Breakdown by CTLA-4 Inhibitors:
    • 17.7.1 Pre-COVID-19 Market Scenario
    • 17.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.8 LAMEA Market Breakdown by Cytokines Targets:
    • 17.8.1 Pre-COVID-19 Market Scenario
    • 17.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.9 LAMEA Market Breakdown by Application:
    • 17.9.1 Pre-COVID-19 Market Scenario
    • 17.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.10 LAMEA Market Breakdown by Immuno Adjuvants:
    • 17.10.1 Pre-COVID-19 Market Scenario
    • 17.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.11 LAMEA Market Breakdown by Immunomodulators:
    • 17.11.1 Pre-COVID-19 Market Scenario
    • 17.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.12 Brazil Checkpoint Inhibitors Market Analysis
    • 17.12.1 Country Adopting Therapeutic Strategies to Enhance Immune-Responsiveness in Prostate Cancer
    • 17.12.2 Pre-COVID-19 Market Scenario
    • 17.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.13 South Africa Checkpoint Inhibitors Market Analysis
    • 17.13.1 Checkpoint Inhibitors Are Also Being Investigated in Combination with Chemotherapy
    • 17.13.2 Pre-COVID-19 Market Scenario
    • 17.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.14 Saudi Arabia Checkpoint Inhibitors Market Analysis
    • 17.14.1 Increasing Importance of Immune Checkpoint Inhibitor Therapy
    • 17.14.2 Pre-COVID-19 Market Scenario
    • 17.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.15 Turkey Checkpoint Inhibitors Market Analysis
    • 17.15.1 Immune Checkpoint Inhibitor Research Under Trials
    • 17.15.2 Pre-COVID-19 Market Scenario
    • 17.15.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.16 UAE Checkpoint Inhibitors Market Analysis
    • 17.16.1 Negative Side of ICI Reported in UAE
    • 17.16.2 Pre-COVID-19 Market Scenario
    • 17.16.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
  • 17.17 Rest of LAMEA Checkpoint Inhibitors Market Analysis
    • 17.17.1 Pre-COVID-19 Market Scenario
    • 17.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

18 Leading Company Profiles

  • 18.1 Competitive Landscape
    • 18.1.1 Collaborations and Partnerships in the Global Market
  • 18.2 Seagen Inc.
    • 18.2.1 Company Snapshot
    • 18.2.2 Company Overview
    • 18.2.3 Company Financial Profile
    • 18.2.4 Company Product Benchmarking
    • 18.2.5 Company Recent Developments
  • 18.3 AGENUS INC.
    • 18.3.1 Company Snapshot
    • 18.3.2 Company Overview
    • 18.3.3 Company Financial Profile
    • 18.3.4 Company Product Benchmarking
    • 18.3.5 Company Recent Developments
  • 18.4 Agilent Technologies
    • 18.4.1 Company Snapshot
    • 18.4.2 Company Overview
    • 18.4.3 Company Financial Profile
    • 18.4.4 Company Product Benchmarking
    • 18.4.5 Company Recent Developments
  • 18.5 AbbVie Inc.
    • 18.5.1 Company Snapshot
    • 18.5.2 Company Overview
    • 18.5.3 Company Financial Profile
    • 18.5.4 Company Product Benchmarking
    • 18.5.5 Company Recent Developments
  • 18.6 xencor
    • 18.6.1 Company Snapshot
    • 18.6.2 Company Overview
    • 18.6.3 Company Financial Profile
    • 18.6.4 Company Product Benchmarking
    • 18.6.5 Company Recent Developments
  • 18.7 Ono pharmaceutical
    • 18.7.1 Company Snapshot
    • 18.7.2 Company Overview
    • 18.7.3 Company Financial Profile
    • 18.7.4 Company Product Benchmarking
    • 18.7.5 Company Recent Developments
  • 18.8 Sanofi SA
    • 18.8.1 Company Snapshot
    • 18.8.2 Company Overview
    • 18.8.3 Company Financial Profile
    • 18.8.4 Company Product Benchmarking
    • 18.8.5 Company Recent Developments
  • 18.9 Eli Lilly and Co
    • 18.9.1 Company Snapshot
    • 18.9.2 Company Overview
    • 18.9.3 Company Financial Profile
    • 18.9.4 Company Product Benchmarking
    • 18.9.5 Company Recent Developments
  • 18.10 Kyowa Hakko Kirin
    • 18.10.1 Company Snapshot
    • 18.10.2 Company Overview
    • 18.10.3 Company Financial Profile
    • 18.10.4 Company Product Benchmarking
    • 18.10.5 Company Recent Developments
  • 18.11 Novartis
    • 18.11.1 Company Snapshot
    • 18.11.2 Company Overview
    • 18.11.3 Company Financial Profile
    • 18.11.4 Company Product Benchmarking
    • 18.11.5 Company Recent Developments
  • 18.12 Pfizer Inc.
    • 18.12.1 Company Snapshot
    • 18.12.2 Company Overview
    • 18.12.3 Company Financial Profile
    • 18.12.4 Company Product Benchmarking
    • 18.12.5 Company Recent Developments
  • 18.13 Roche
    • 18.13.1 Company Snapshot
    • 18.13.2 Company Overview
    • 18.13.3 Company Financial Profile
    • 18.13.4 Company Product Benchmarking
    • 18.13.5 Company Recent Developments
  • 18.14 Merck & Co.
    • 18.14.1 Company Snapshot
    • 18.14.2 Company Overview
    • 18.14.3 Company Financial Profile
    • 18.14.4 Company Product Benchmarking
    • 18.14.5 Company Recent Developments
  • 18.15 Incyte
    • 18.15.1 Company Snapshot
    • 18.15.2 Company Overview
    • 18.15.3 Company Financial Profile
    • 18.15.4 Company Product Benchmarking
    • 18.15.5 Company Recent Developments
  • 18.16 Regeneron pharmaceuticals Inc.
    • 18.16.1 Company Snapshot
    • 18.16.2 Company Overview
    • 18.16.3 Company Financial Profile
    • 18.16.4 Company Product Benchmarking
    • 18.16.5 Company Recent Developments
  • 18.17 Amgen Inc
    • 18.17.1 Company Snapshot
    • 18.17.2 Company Overview
    • 18.17.3 Company Financial Profile
    • 18.17.4 Company Product Benchmarking
    • 18.17.5 Company Recent Developments
  • 18.18 Bristol Myers Squibb
    • 18.18.1 Company Snapshot
    • 18.18.2 Company Overview
    • 18.18.3 Company Financial Profile
    • 18.18.4 Company Product Benchmarking
    • 18.18.5 Company Recent Developments
  • 18.19 Clovis Oncology
    • 18.19.1 Company Snapshot
    • 18.19.2 Company Overview
    • 18.19.3 Company Financial Profile
    • 18.19.4 Company Product Benchmarking
    • 18.19.5 Company Recent Developments
  • 18.20 Heptares Therapeutics Ltd.
    • 18.20.1 Company Snapshot
    • 18.20.2 Company Overview
    • 18.20.3 Company Financial Profile
    • 18.20.4 Company Product Benchmarking
    • 18.20.5 Company Recent Developments

19 Conclusions & Recommendations Visiongain

  • 19.1 Concluding Remarks from Visiongain
  • 19.2 Recommendations for Market Players
  • 19.3 North America to Dominate the Global Checkpoint Inhibitors Market
    • 19.3.1 North America to Hold the Largest Share During Forecast Period
    • 19.3.2 Asia-Pacific Region to Emerge as the Fastest Growing Market

20 Glossary Terms

List of Tables

  • Table 1. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 2. Global Checkpoint Inhibitors Market Snapshot, 2021 & 2031 (US$billion, CAGR %)
  • Table 3. Adverse Events Associated with Immune-Checkpoint Blockade
  • Table 4. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 5. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 6. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 7. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 8. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 9. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 10. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 11. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 12. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 13. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 14. Comparison of PD-L1-PD-L2 ligands
  • Table 15. Summary of Anti-PD-1/PD-L1 Therapies Approved Indications
  • Table 16. Summary of Anti-PD-1/PD-L1 Therapies Approved Indications (continued)
  • Table 17. PD-1/PD-L1 Agents Pipeline Drugs
  • Table 18. Pembrolizumab Approved Indications
  • Table 19. Nivolumab Approved Indications
  • Table 20. Atezolizumab Approved Indications
  • Table 21. Regeneron's NSCLC Development Program
  • Table 22. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 23. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 24. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 25. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 26. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 27. Avelumab Approved Indications
  • Table 28. Durvalumab Approved Indication
  • Table 29. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 30. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 31. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 32. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 33. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 34. CTLA-4 Agents in Pipeline
  • Table 35. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 36. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 37. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 38. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 39. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 40. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 41. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 42. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 43. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 44. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 45. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 46. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 47. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 48. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 49. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 50. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 51. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 52. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 53. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 54. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 55. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 56. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 57. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 58. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 59. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 60. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 61. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 62. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 63. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 64. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 65. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 66. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 67. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 68. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 69. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 70. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 71. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
  • Table 72. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
  • Table 73. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
  • Table 74. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 75. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 76. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
  • Table 77. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
  • Table 78. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
  • Table 79. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
  • Table 80. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 81. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 82. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 83. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 84. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 85. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 86. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 87. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 88. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 89. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 90. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 91. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 92. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 93. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 94. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 95. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 96. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 97. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 98. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 99. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 100. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 101. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 102. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 103. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 104. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 105. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 106. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 107. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 108. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 109. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 110. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 111. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 112. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 113. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 114. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 115. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 116. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 117. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 118. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 119. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 120. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 121. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 122. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 123. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 124. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 125. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 126. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 127. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 128. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 129. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 130. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 131. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 132. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 133. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 134. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 135. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 136. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
  • Table 137. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
  • Table 138. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
  • Table 139. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
  • Table 140. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 141. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 142. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 143. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 144. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 145. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 146. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 147. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 148. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 149. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 150. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 151. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 152. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 153. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 154. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 155. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 156. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 157. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 158. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 159. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 160. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 161. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 162. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 163. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 164. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 165. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 166. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 167. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 168. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 169. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 170. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 171. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 172. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 173. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 174. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 175. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 176. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 177. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 178. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 179. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 180. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 181. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 182. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 183. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 184. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 185. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 186. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 187. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 188. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 189. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 190. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 191. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 192. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 193. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 194. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 195. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 196. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 197. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 198. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 199. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 200. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 201. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 202. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 203. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 204. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 205. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 206. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 207. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 208. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 209. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 210. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 211. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 212. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 213. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 214. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 215. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 216. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
  • Table 217. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
  • Table 218. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
  • Table 219. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
  • Table 220. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 221. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 222. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 223. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 224. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 225. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 226. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 227. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 228. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 229. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 230. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 231. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 232. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 233. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 234. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 235. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 236. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 237. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 238. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 239. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 240. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 241. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 242. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 243. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 244. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 245. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 246. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 247. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 248. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 249. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 250. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 251. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 252. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 253. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 254. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 255. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 256. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 257. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 258. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 259. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 260. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 261. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 262. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 263. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 264. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 265. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 266. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 267. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 268. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 269. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 270. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 271. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 272. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 273. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 274. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 275. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 276. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 277. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 278. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 279. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 280. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 281. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 282. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 283. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 284. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 285. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 286. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 287. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 288. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 289. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 290. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 291. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 292. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 293. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 294. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 295. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 296. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
  • Table 297. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
  • Table 298. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
  • Table 299. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
  • Table 300. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 301. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 302. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 303. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 304. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 305. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 306. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 307. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 308. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 309. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 310. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 311. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 312. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 313. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 314. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 315. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 316. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 317. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 318. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 319. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 320. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 321. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 322. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 323. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 324. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 325. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 326. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 327. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 328. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 329. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 330. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 331. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 332. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 333. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 334. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 335. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 336. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 337. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 338. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 339. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 340. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 341. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 342. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 343. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 344. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 345. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 346. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 347. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 348. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 349. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 350. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 351. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 352. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 353. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 354. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 355. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 356. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 357. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 358. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 359. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 360. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 361. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 362. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 363. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 364. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 365. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))
  • Table 366. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
  • Table 367. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
  • Table 368. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
  • Table 369. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
  • Table 370. Seagen Inc.: Company Information
  • Table 371. Seagen Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 372. Seagen Inc.: Company Product and Service Benchmarking
  • Table 373. Seagen Inc.: Company Recent Developments till Feb,2021
  • Table 374. AGENUS INC.: Company Information
  • Table 375. AGENUS INC.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 376. AGENUS INC.: Company Product and Service Benchmarking
  • Table 377. AGENUS INC.: Company Recent Developments till Feb,2021
  • Table 378. Agilent Technologies: Company Information
  • Table 379. Agilent Technologies: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 380. Agilent Technologies: Company Product and Service Benchmarking
  • Table 381. Agilent Technologies: Company Recent Developments till Feb,2021
  • Table 382. AbbVie Inc.: Company Information
  • Table 383. AbbVie Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 384. AbbVie Inc.: Company Product and Service Benchmarking
  • Table 385. AbbVie Inc.: Company Recent Developments till Feb,2021
  • Table 386. xencor: Company Information
  • Table 387. xencor : Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 388. xencor : Company Product and Service Benchmarking
  • Table 389. xencor: Company Recent Developments till Feb,2021
  • Table 390. Ono pharmaceutical : Company Information
  • Table 391. Ono pharmaceutical : Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 392. Ono pharmaceutical : Company Product and Service Benchmarking
  • Table 393. Ono pharmaceutical : Company Recent Developments till Feb,2021
  • Table 394. Sonafi: Company Information
  • Table 395. Sanofi: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 396. Sanofi: Company Product and Service Benchmarking
  • Table 397. Sanofi: Company Recent Developments till Feb,2021
  • Table 398. Eli Lilly And Co: Company Information
  • Table 399. Eli Lilly And Co: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 400. Eli Lilly And Co: Company Product and Service Benchmarking
  • Table 401. Eli Lilly And Co: Company Recent Developments till Feb,2021
  • Table 402. Kyowa Hakko Kirin : Company Information
  • Table 403. Kyowa Hakko Kirin : Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 404. Kyowa Hakko Kirin : Company Product and Service Benchmarking
  • Table 405. Kyowa Hakko Kirin : Company Recent Developments till Feb,2021
  • Table 406. Novartis : Company Information
  • Table 407. Novartis : Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 408. Novartis : Company Product and Service Benchmarking
  • Table 409. Novartis: Company Recent Developments till Feb,2021
  • Table 410. Pfizer Inc. : Company Information
  • Table 411. Pfizer Inc. : Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 412. Pfizer Inc. : Company Product and Service Benchmarking
  • Table 413. Pfizer Inc. : Company Recent Developments till Feb,2021
  • Table 414. Roche: Company Information
  • Table 415. Roche: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 416. Roche: Company Product and Service Benchmarking
  • Table 417. Roche: Company Recent Developments till Feb,2021
  • Table 418. Merck & Co.: Company Information
  • Table 419. Merck & Co.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 420. Merck & Co. : Company Product and Service Benchmarking
  • Table 421. Merck & Co.: Company Recent Developments till Feb,2021
  • Table 422. Incyte : Company Information
  • Table 423. Incyte: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 424. Incyte : Company Product and Service Benchmarking
  • Table 425. Incyte: Company Recent Developments till Feb,2021
  • Table 426. Regeneron pharmaceuticals Inc.: Company Information
  • Table 427. Regeneron pharmaceuticals Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 428. Regeneron pharmaceuticals Inc.: Company Product and Service Benchmarking
  • Table 429. Regeneron pharmaceuticals Inc.: Company Recent Developments till Feb,2021
  • Table 430. Amgen Inc: Company Information
  • Table 431. Amgen Inc: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 432. Amgen Inc: Company Product and Service Benchmarking
  • Table 433. Amgen Inc: Company Recent Developments till Feb,2021
  • Table 434. Bristol Myers Squibb: Company Information
  • Table 435. Bristol Myers Squibb: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 436. Bristol Myers Squibb: Company Product and Service Benchmarking
  • Table 437. Bristol Myers Squibb: Company Recent Developments till Feb,2021
  • Table 438. Clovis Oncology: Company Information
  • Table 439. Clovis Oncology: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 440. Clovis Oncology: Company Product and Service Benchmarking
  • Table 441. Clovis Oncology: Company Recent Developments till Feb,2021
  • Table 442. Heptares Therapeutics Ltd.: Company Information
  • Table 443. Heptares Therapeutics Ltd.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Table 444. Heptares Therapeutics Ltd.: Company Product and Service Benchmarking
  • Table 445. Heptares Therapeutics Ltd.: Company Recent Developments till Feb,2021
  • Table 446. Abbreviations Used in Checkpoint Inhibitors
  • Table 447. Term Meaning

List of Figures

  • Figure 1. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
  • Figure 2. Global Checkpoint Inhibitors Market Segmentation
  • Figure 3. Global Checkpoint Inhibitors for Treating Cancer Market: Market Trends
  • Figure 4. Potential Targets for checkpoint inhibition in clinical Evaluation
  • Figure 5. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
  • Figure 6. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 7. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 8. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 9. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 10. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Category, 2021, 2026, 2031 (%)
  • Figure 11. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
  • Figure 12. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 13. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 14. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 15. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 16. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by PD1 Inhibitors, 2021, 2026, 2031 (%)
  • Figure 17. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 18. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 19. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 20. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 21. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 22. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by PDL1 Inhibitors, 2021, 2026, 2031 (%)
  • Figure 23. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 24. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 25. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 26. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 27. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 28. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 29. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 30. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 31. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 32. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 33. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Cytokines Targets, 2021, 2026, 2031 (%)
  • Figure 34. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
  • Figure 35. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 36. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 37. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 38. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 39. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Immuno Adjuvants, 2021, 2026, 2031 (%)
  • Figure 40. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
  • Figure 41. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 42. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 43. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 44. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 45. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
  • Figure 46. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 47. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 48. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 49. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 50. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Application, 2021, 2026, 2031 (%)
  • Figure 51. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
  • Figure 52. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 53. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 54. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 55. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 56. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Region, 2021, 2026, 2031 (%)
  • Figure 57. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))
  • Figure 58. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 59. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 60. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 61. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 62. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
  • Figure 63. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 64. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 65. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 66. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 67. North America Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
  • Figure 68. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
  • Figure 69. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
  • Figure 70. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
  • Figure 71. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 72. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 73. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
  • Figure 74. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
  • Figure 75. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
  • Figure 76. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
  • Figure 77. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 78. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 79. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 80. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 81. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 82. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 83. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 84. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 85. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 86. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 87. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 88. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 89. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 90. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 91. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 92. North America Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 93. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
  • Figure 94. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 95. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 96. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 97. North America Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 98. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
  • Figure 99. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 100. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 101. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 102. North America Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 103. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
  • Figure 104. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 105. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 106. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 107. North America Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 108. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
  • Figure 109. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 110. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 111. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 112. North America Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 113. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 114. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 115. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 116. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 117. US Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 118. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 119. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 120. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 121. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 122. Canada Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 123. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 124. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031(USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 125. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 126. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 127. Mexico Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 128. Europe Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
  • Figure 129. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
  • Figure 130. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 131. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 132. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 133. Europe Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 134. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
  • Figure 135. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
  • Figure 136. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
  • Figure 137. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
  • Figure 138. Europe Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (L - Shaped Recovery)
  • Figure 139. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
  • Figure 140. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 141. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 142. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 143. Europe Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 144. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 145. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 146. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 147. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 148. Europe Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 149. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 150. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 151. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 152. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 153. Europe Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 154. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 155. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 156. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 157. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 158. Europe Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 159. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
  • Figure 160. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 161. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 162. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 163. Europe Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 164. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
  • Figure 165. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 166. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 167. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 168. Europe Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 169. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
  • Figure 170. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 171. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 172. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 173. Europe Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 174. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
  • Figure 175. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 176. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 177. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 178. Europe Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 179. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 180. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 181. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 182. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 183. Germany Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 184. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 185. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 186. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 187. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 188. UK Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 189. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 190. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 191. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 192. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 193. France Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 194. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 195. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 196. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 197. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 198. Italy Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 199. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 200. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 201. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 202. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 203. Spain Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 204. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 205. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 206. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 207. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 208. Rest of Europe Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 209. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
  • Figure 210. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
  • Figure 211. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 212. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 213. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 214. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 215. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
  • Figure 216. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
  • Figure 217. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
  • Figure 218. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
  • Figure 219. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (L - Shaped Recovery)
  • Figure 220. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
  • Figure 221. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 222. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 223. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 224. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 225. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 226. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 227. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 228. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 229. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 230. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 231. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 232. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 233. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 234. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 235. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 236. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 237. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 238. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 239. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 240. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
  • Figure 241. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 242. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 243. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 244. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 245. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
  • Figure 246. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 247. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 248. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 249. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 250. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
  • Figure 251. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 252. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 253. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 254. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 255. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
  • Figure 256. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 257. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 258. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 259. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 260. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 261. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 262. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 263. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 264. China Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 265. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 266. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 267. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 268. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 269. India Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 270. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 271. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 272. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 273. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 274. Japan Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 275. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 276. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 277. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 278. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 279. South Korea Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 280. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 281. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 282. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 283. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 284. Australia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 285. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 286. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 287. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 288. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 289. Rest of Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 290. LAMEA Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Country, 2021, 2026, 2031 (%)
  • Figure 291. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))
  • Figure 292. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 293. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 294. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 295. LAMEA Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 296. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%))
  • Figure 297. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (V - Shaped Recovery)
  • Figure 298. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (W - Shaped Recovery)
  • Figure 299. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (U - Shaped Recovery)
  • Figure 300. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%)) (L - Shaped Recovery)
  • Figure 301. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))
  • Figure 302. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 303. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 304. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 305. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 306. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 307. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 308. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 309. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 310. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 311. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 312. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 313. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 314. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 315. LAMEA Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 316. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))
  • Figure 317. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 318. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 319. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 320. LAMEA Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 321. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))
  • Figure 322. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 323. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 324. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 325. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 326. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))
  • Figure 327. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 328. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 329. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 330. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 331. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))
  • Figure 332. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 333. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 334. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 335. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 336. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))
  • Figure 337. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 338. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 339. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 340. LAMEA Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 341. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 342. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 343. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 344. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 345. Brazil Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 346. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 347. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 348. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 349. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 350. South Africa Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 351. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 352. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 353. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 354. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 355. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 356. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 357. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 358. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 359. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 360. Turkey Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 361. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 362. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 363. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 364. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 365. UAE Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 366. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))
  • Figure 367. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(V-Shape Recovery)
  • Figure 368. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(W-Shape Recovery)
  • Figure 369. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(U-Shape Recovery)
  • Figure 370. Rest of LAMEA Checkpoint Inhibitors for Treating Cancer Market by Value, 2021-2031 (USD Mn, AGR (%))(L-Shape Recovery)
  • Figure 371. Global Checkpoint Inhibitors Market Share, 2020
  • Figure 372. Seagen Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 373. Seagen Inc.: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 374. Seagen Inc.: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 375. Seagen Inc.: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 376. AGENUS INC.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 377. AGENUS INC.: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 378. AGENUS INC.: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 379. AGENUS INC.: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 380. Agilent Technologies: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 381. Agilent Technologies: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 382. Agilent Technologies: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 383. Agilent Technologies: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 384. AbbVie Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 385. AbbVie Inc.: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 386. AbbVie Inc.: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 387. AbbVie Inc.: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 388. xencor: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 389. xencor : Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 390. xencor : Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 391. xencor : Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 392. Ono pharmaceutical : Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 393. Ono pharmaceutical : Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 394. Ono pharmaceutical: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 395. Ono pharmaceutical : Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 396. Sanofi: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 397. Sanofi: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 398. Sanofi: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 399. Sanofi: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 400. Eli Lilly And Co: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 401. Eli Lilly And Co: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 402. Eli Lilly And Co: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 403. Eli Lilly And Co: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 404. Kyowa Hakko Kirin : Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 405. Kyowa Hakko Kirin : Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 406. Kyowa Hakko Kirin : Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 407. Kyowa Hakko Kirin : Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 408. Novartis: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 409. Novartis : Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 410. Novartis : Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 411. Novartis : Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 412. Pfizer Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 413. Pfizer Inc. : Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 414. Pfizer Inc. : Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 415. Pfizer Inc. : Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 416. Roche: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 417. Roche: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 418. Roche: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 419. Roche: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 420. Merck & Co. : Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 421. Merck & Co. : Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 422. Merck & Co. : Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 423. Merck & Co. : Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 424. Incyte: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 425. Incyte : Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 426. Incyte: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 427. Incyte: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 428. Regeneron pharmaceuticals Inc.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 429. Regeneron pharmaceuticals Inc.: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 430. Regeneron pharmaceuticals Inc.: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 431. Regeneron pharmaceuticals Inc.: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 432. Amgen Inc: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 433. Amgen Inc: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 434. Amgen Inc: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 435. Amgen Inc: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 436. Bristol Myers Squibb: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 437. Bristol Myers Squibb: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 438. Bristol Myers Squibb: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 439. Bristol Myers Squibb: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 440. Clovis Oncology: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 441. Clovis Oncology: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 442. Clovis Oncology: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 443. Clovis Oncology: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 444. Heptares Therapeutics Ltd.: Company Revenue 2016-2020 (US$Mn, AGR %)
  • Figure 445. Heptares Therapeutics Ltd.: Company Operating Income 2016-2020 (US$Mn, AGR %)
  • Figure 446. Heptares Therapeutics Ltd.: Company Net Income 2016-2020 (US$Mn, AGR %)
  • Figure 447. Heptares Therapeutics Ltd.: Company EBITDA2016-2020 (US$Mn, AGR %)
  • Figure 448. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Region, 2021, 2026, 2031 (%)

List of Companies Profiled in the report:

  • Seagen Inc.,
  • Agenus Inc. (Agenus)
  • Agilent Technologies, Inc.
  • AbbVie Inc. (AbbVie)
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Clovis Oncology, Inc.
  • Eli Lilly and Company
  • Heptares Therapeutics Ltd.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc. (Pfizer)
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG (Roche)
  • Sanofi SA
  • Xencor, Inc.

List of Other Companies Mentioned in the report:

  • AbbVie
  • Abramson Cancer Center
  • Admune Therapeutics
  • Aduro Biotech
  • Advaxis, Inc.
  • Agenus Inc.
  • Agilent Technologies
  • Alcon
  • Amgen
  • Amplimmune
  • AnaptysBio
  • Apexigen, Inc.
  • AREVA Med
  • ARIAD Pharmaceuticals, Inc.
  • Array BioPharma
  • AstraZeneca
  • Aurigene Discovery Technologies
  • Basilea Pharmaceutica Ltd.
  • BeiGene
  • Bristol-Myers Squibb
  • Calithera Biosciences Inc.
  • cCAM Biotherapeutics
  • Celgene
  • Celldex Therapeutics Inc.
  • Chugai
  • Clal Biotech
  • Clovis Oncology, Inc.
  • CoStim Pharmaceuticals
  • CureTech, Ltd.
  • Curis, Inc.
  • Daiichi Sankyo Company, Limited
  • Dako
  • DNAtrix
  • Dynavax
  • Eddingpharm
  • Eisai Co., Ltd.
  • Eli Lilly
  • Exelixis, Inc.
  • GE Healthcare
  • GeneCentric Diagnostics, Inc.
  • Heptares Therapeutics
  • IBM
  • Immune Design
  • Immunocore Limited
  • Immutep
  • Incyte
  • Innate Pharma
  • Inovio Pharmaceuticals
  • IOmet Pharma Ltd.
  • Janssen Biotech, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Kyowa Hakko Kirin
  • MacroGenicS Inc.
  • Medarex
  • MedImmune
  • Medivation, Inc
  • Merck & Co.
  • Merus N.V.
  • Moderna Therapeutics
  • Moffitt Cancer Center
  • MS
  • NanoString Technologies, Inc.
  • NEC Corporation
  • NewLink Genetics
  • Novartis
  • Oncothyreon Inc.
  • Ono Pharmaceutical
  • Peregrine Pharmaceuticals
  • Pfizer, Inc.
  • Plexxikon Inc.
  • Prima Biomed
  • Regeneron Pharmaceuticals
  • Roche
  • Sandoz
  • Sanofi
  • Seattle Genetics, Inc.
  • Sosei Group Corporation
  • Surface Oncology
  • Syndax Pharmaceuticals
  • Syros Pharmaceuticals, Inc.
  • TARIS Biomedical LLC
  • TESARO, Inc.
  • TetraLogic Pharmaceuticals Corporation
  • Transgene SA
  • Western Oncolytics
  • Xencor

List of Associations Mentioned in the Report:

  • Cancer Research Institute
  • Central Social Insurance Medical Council
  • Data Monitoring Committee
  • Early Access to Medicines Scheme
  • European Cancer Congress
  • European Medicines Agency
  • European Organisation for Research and Treatment of Cancer
  • MD Anderson Cancer Center
  • Medicines and Healthcare Products Regulatory Agency
  • Ministry of Health, Labour, and Welfare
  • National Cancer Institute
  • National Institute for Health and Clinical Excellence
  • QIMR Berghofer Medical Research Institute
  • University of Pittsburgh
  • Yamaguchi University